RAD-x continues German expansion - Gilde Healthcare

RAD-x continues German expansion

April 17, 2018

Utrecht, The Netherlands – Gilde Healthcare portfolio company RAD-x, the pan-European operator in diagnostic imaging, has announced that it has acquired Teleradiologisches Zentrum Koblenz (TelradKo). TelradKo provides teleradiology services to hospitals and hospital-based imaging centres in Germany. The combination with RAD-x enables TelradKo to accelerate its expansion and continue investing in the latest technology to establish itself as the leading provider of teleradiology services to small and medium sized hospitals.

 

About RAD-x

RAD-x is a fast-growing pan-European operator of diagnostic imaging centres, based on a network of local and regional centres. The network currently has a staff of over 350 healthcare professionals working in diagnostic imaging centres and hospitals. RAD-x’s growth model is based on the integration in its network of existing leading local and regional medical imaging centres and offering their radiologists to become shareholders of RAD-x. For more information, visit the company’s website at www.RAD-x.eu

About TelradKo

TelradKo is a provider of teleradiology services to hospitals and hospital-based imaging centres in Germany founded in 2014. For more information, visit the company’s website at www.telradko.de

About Gilde Healthcare

Gilde Healthcare is a specialized European healthcare investor managing two business lines: a venture & growth capital fund and a lower mid-market buy-out fund. Gilde Healthcare’s venture & growth capital fund invests in medtech, diagnostics, digital health and therapeutics. The portfolio companies are based in Europe and North America. Gilde Healthcare’s lower mid-market buy-out fund invests in profitable European healthcare services companies with a focus on the Benelux and Dach-region. The portfolio consists of healthcare providers, suppliers of medical products and other service providers in the healthcare market. Gilde Healthcare has raised €800 million ($1 billion) for its specialized funds. For more information, visit the company’s website at www.gildehealthcare.com

More news

Gilde Healthcare company SpyGlass Pharma announces pricing of initial public offering at NASDAQ

SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma”), a late-stage biopharmaceutical company, today announced the pricing of its initial public offering of 9,375,000 shares of its common stock at a public offering price of $16.00 per...
February 6, 2026

Gilde Healthcare appoints Matthew Stork as CEO and Maarten Jaspers as Finance Director of its neuroimaging technology group

The neuroimaging group, consisting of Artinis and NIRx, leading in functional Near-Infrared Spectroscopy (fNIRS) solutions, has appointed Matthew Stork as Chief Executive Officer (CEO) and Maarten Jaspers as Finance Director. Matthew Stork has over 25...
February 5, 2026

Gilde Healthcare Company Volta Medical publishes RESTART Trial Results on AI Solutions in Recurrent Atrial Fibrillation

Volta Medical’s artificial intelligence (AI) solution demonstrated 83% freedom from atrial fibrillation (AF) at 12 months after a single procedure in patients with recurrent AF and isolated pulmonary veins following prior ablation Volta Medical, committed...
February 3, 2026